Insider Selling: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Sells $23,580.00 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Timothy J. Sangiovanni sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $23,580.00. Following the completion of the transaction, the senior vice president now directly owns 16,341 shares of the company’s stock, valued at $128,440.26. The trade was a 15.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $8.07 on Monday. The stock has a market capitalization of $430.74 million, a P/E ratio of -4.10 and a beta of 2.00. Zevra Therapeutics, Inc. has a 12-month low of $4.20 and a 12-month high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The firm’s 50-day moving average is $8.22 and its two-hundred day moving average is $8.07.

Institutional Trading of Zevra Therapeutics

A number of hedge funds have recently bought and sold shares of the company. International Assets Investment Management LLC lifted its stake in shares of Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after purchasing an additional 5,940 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Zevra Therapeutics during the fourth quarter worth about $94,000. Hunter Associates Investment Management LLC acquired a new stake in Zevra Therapeutics in the 3rd quarter worth about $92,000. XTX Topco Ltd purchased a new stake in Zevra Therapeutics in the 3rd quarter valued at about $94,000. Finally, Intech Investment Management LLC acquired a new position in shares of Zevra Therapeutics during the 3rd quarter valued at about $95,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Analyst Upgrades and Downgrades

ZVRA has been the subject of a number of research analyst reports. Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 29th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group reduced their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zevra Therapeutics currently has an average rating of “Buy” and a consensus price target of $21.57.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.